Penetration of antimicrobial agents into the prostate

Chemotherapy

Volumn 49, Issue 6, 2003, Pages 269-279

  Charalabopoulos, Konstantin ^a,b,c   Karachalios, George ^a,b   Baltogiannis, Dimitrios ^a   Charalabopoulos, Alexander ^a   Giannakopoulos, Xenofon ^a   Sofikitis, Nikolaos ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b RED CROSS HOSPITAL   (Greece)

^c NONE   (Greece)

Author keywords

Antibiotics; Antimicrobial agents; Prostate; Prostatitis

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFACLOR; CEFALEXIN; CEFALOTIN; CEFRADINE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; GENTAMICIN; LINCOSAMIDE DERIVATIVE; MACROLIDE; MEZLOCILLIN; MONOBACTAM DERIVATIVE; NETILMICIN; NITROFURANTOIN; NORFLOXACIN; OFLOXACIN; PENICILLIN DERIVATIVE; PIPERACILLIN; QUINOLONE DERIVATIVE; SULFONAMIDE; TETRACYCLINE DERIVATIVE; TOBRAMYCIN; UNINDEXED DRUG;

ANURIA; CHRONIC PROSTATITIS; DISSOCIATION CONSTANT; DOSE RESPONSE; DRUG DIFFUSION; DRUG EFFECT; DRUG EFFICACY; DRUG PENETRATION; DRUG TISSUE LEVEL; HUMAN; IC 50; LIPID SOLUBILITY; NONHUMAN; PH; PKA; PLASMA; PRIORITY JOURNAL; PROSTATE ADENOMA; PROSTATE FLUID; PROTEIN BINDING; REVIEW; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; PROSTATE; PROSTATITIS;

EID: 0346753571     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074526     Document Type: Review

References (79)

1. Meares EM: Prostatitis. Med Clin North Am 1991;75:405-424.
2. Winningham DC, Nemoy NJ, Stamey TA: Diffusion of antibiotics from plasma into prostatic tissue. Nature 1968;219:139-143.
3. Reeves DS, Blacklock NJ: Secretion of antibiotics into human prostatic fluid; in Kass EH, Brumfitt W (eds): Infections of the Urinary Tract. Proceedings of the 3rd International Symposium on Pyelonephritis at the Royal College of Physicians, London, England, 1975. Chicago, University of Chicago Press, 1978, pp 166-170.
4. Pfau A, Perlberg S, Shapira A: The pH of the prostatic fluid in health and disease: Implications of treatment in chronic bacterial prostatitis. J Urol 1978;119:384-387.
5. Stamey TA, Meares EM, Winningham DG: Chronic bacterial prostatitis and the diffusion of drugs into prostatic fluid. J Urol 1970;103: 187-194.
6. Juricic C, Klippel KF, Sietzen W, et al: Concentration of amoxycillin and clavunalate in the prostate tissue and in serum: A pharmacokinetic study. Proc 15th Int Congr Chemother, Istanbul 1987.
7. Scaglione F, Ferrara F, Logo R, et al: Pharmacokinetics and tissue penetration of clavulanic acid and amoxicillin given in combination and in a single intake. Proc 6th Mediterr Congr Chemother, Taormina, 22-27 May, 1988.
8. Kjaer TB, Madsen PO: Prostatic fluid and tissue concentrations of ampicillin after administration of hetacillin ester (BL-P1761). Invest Urol 1976;14:57-59.
9. Tunn U, Adam D: Diffusion and pharmacokinetics of piperacillin in prostatic tissue. Curr Chemother 1980;1:305-306.
10. Ponchietti R, Raugei A, Dami A, Trippitelli A: Piperacillin in the treatment of chronic bacterial prostatitis (in Italian). Minerva Urol Nefrol 1987;39:343-346.
11. Naber KG, Adam D: Tissue concentrations of mezlocillin in benign hypertrophy of the prostate following intravenous bolus injection versus infusion. J Antimicrob Chemother 1983; 11(suppl C):17-23.
12. Smith RP, Wilbur HJ, Bassey C, Baltch AL: Azlocillin and mezlocillin concentration in human prostatic tissue. Chemotherapy 1988;34: 267-271.
13. Gould JG, Meikle G, Cooper DL, Horton R: Temocillin concentrations in human tissues. Drugs 1985;29(suppl 5):167-170.
14. Adam D, Hofstetter AG, Jacoby W: Studies on the diffusion of cephradine into human tissues. Infection 1976;4(suppl 2):105-107.
15. Symes JM, Jarvis JD, Tresidder GC: An appraisal of cephalexin monohydrate levels in semen and prostatic tissue. Chemotherapy 1974;20:257-262.
16. Litvak AS, Frank CD, Vaught SK, McRoberts JW: Cephazolin and cephalexin levels in prostatic tissue and serum. Urology 1976;7:497-498.
17. Smith RP, Schmid GP, Baltch AL, Sutphen NT, Hammer MC: Concentration of cefaclor in human prostatic tissue. Am J Med Sci 1981; 281:19-24.
18. Adam D, Hofstetter AG, Eisenberger F: Zur Diffusion von Cefamandol in das Prostategewebe. Med Klin 1979;74:235-238.
19. Raifer J, Jacob LS, Pitkin D: Prostatic tissue levels following cefonicid administration. 22nd lnterscience Conference on Antimicrobial Agents and Chemotherapy, Florida 1982.
20. Fujimura N, Yuasa M, Yuasa K, et al: Fundamental and clinical studies on cefotetan (YM09330) in urological field. Chemotherapy 1982;30:733-740.
21. Charton M, Panis G, Brisset JM, Veillon B, Vallancien G, Selles JP: Passage of cefotiam into prostatic tissue. Pathol Biol (Paris) 1985; 33:530-532.
22. Pelz K, Marcushen M, Erhart KP, et al: Konzentration von Cefotaxim in verschiedenen menschlichen Geweben. Infection 1980;8 (suppl 4):S442-S444.
23. Adam D, Naber K: Concentrations of ceftriaxone in prostate adenoma tissue. Chemotherapy 1984;30:1-6.
24. Abbas AMA, Taylor MC, Da Silva C, Francis RA, Bennet C: Penetration of ceftazidime into the human prostate gland following intravenous injection. J Antimicrob Chemother 1985; 15:119-121.
25. Miyagawa I, Goto H, Nakashita E, et al: Clinical studies of cefmenoxime concentrations in prostatic tissue and bladder wall (in Japanese). Jpn J Antibiot 1984;37:787-790.
26. Katoh N, Sugiyama T, Ono Y, Hirabayashi S: Diffusion of cefmenoxime into prostatic fluid in the patients with acute prostatitis (in Japanese). Hinyokika Kiyo 1990;36:1287-1293.
27. Melloni D, Ammatuna P, Formica P, Falletta V, Gaglio F, Cacciatore M, Messina G: Pharmacokinetic study on adenomatous prostate tissue concentrations of cefoperazone. Clinical efficacy and patient tolerance of intramuscular cefoperazone treatment of chronic bacterial prostatitis. Chemotherapy 1989;35:410-415.
28. Saxby MF, Arkell DG, Andrews JM, Wise R: Penetration of cefpirome into prostatic tissue. J Antimicrob Chemother 1990;25:458-490.
29. Sasagawa I: Study on the concentration of cefminox sodium in serum and prostatic tissue (in Japanese). Hinyokika Kiyo 1990;36:737-739.
30. Nishimura K, Habuchi T, Nishio Y, et al: Effects of CS-807 on urinary tract infections and its transfer into prostate. Chemotherapy (Tokyo) 1988;36(suppl 1):784-787.
31. Naber G, Kinzig M, Adam D, et al: Concentrations of cefpodoxime in plasma, ejaculate and in prostatic fluid and adenoma tissue. Infection 1991;19:34-39.
32. Becopoulos T, Georgoulias D, Constantinides C, Stathakis H, Kosmidis J: Acute prostatitis: Which antibiotic to use first. J Chemother 1990;2:244-246.
33. Adam VD, Hofstetter AG, Reichart B, Schneider C, Wolff H, Koch E: Zur Diffusion von Cefazedon in das Herzmuskel-, Prostata-und Hautgewebe sowie in die Gallenflüssigkeit. Arzneimittelforschung 1979;29:1901-1904.
34. Madsen PO, Dhruv R, Friedhoff LT: Aztreonam concentrations in human prostatic tissue. Antimicrob Agents Chemother 1984;26:20-21.
35. Ammatuna P, Romano C, Falletta C, Tripi M, Di Trapani D, Formica P, Pavone-Macaluso M: Concentration of aztreonam in plasma, urine, and seminal fluid of patients with chronic prostatitis (in Italian). Arch Ital Urol Nefrol Androl 1992;64:177-181.
36. Ito Y, Takeda A, Kanematsu M, et al: Clinical studies of imipenem/cilastatin sodium in complicated urinary tract infections and drug concentrations in human kidney and prostate. Chemotherapy (Tokyo) 1985;33(suppl 4):825-833.
37. Suzuki K, Tamai H, Naide Y, et al: Diffusion into human prostatic fluids and clinical evaluation of imipenem/cilastatin sodium in urinary tract infections. Chemotherapy (Tokyo) 1985; 33(suppl 4):793-810.
38. Shindo K, Hori T, Hayashi M, Kiyokawa S, Maeda K, Iwasaki S, Maruta N, Yamada J, Morimitsu H, Taide M, Hoshino K, Shimomae H, Matsuo R, Suzu H, Nishimura N, Hashiguchi J, Saito Y: Efficacy and safety of intramuscular imipenem/cilastatin (IPM/CS) for complicated urinary tract infections (in Japanese). Jpn J Antibiot 1997;50:628-639.
39. Dyderski S, Sokolowski W: Gentamicin level in the prostate and its pharmacokinetics in patients with benign prostatic hypertrophy (in Polish). Pol Tyg Lek 1990;45:517-519.
40. Sharer WC, Fair WR: The pharmacokinetics of antibiotic diffusion in bacterial prostatitis. Prostate 1982;3:139-148.
41. Hess JM, Stamex TA: The passage of tetracyclines across epithelial membranes with special reference to prostatic epithelium. Prostate 1971;106:253-256.
42. Hensle TW, Prout GR, Griffin P: Minocycline diffusion into benign prostatic hyperplasia. J Urol 1977;118; 609-611.
43. Fair W: Diffusion of minocycline into prostatic secretions in dogs. Urology 1974;3:339-344.
44. Baumueller A, Madsen PO: Secretion of various antimicrobial substances in dogs with experimental bacterial prostatitis. Urol Res 1977; 5:215-218.
45. Panzer JD, Brown DC, Epstein WL, Lipson RL, Mahaffey HW, Atkinson WH: Clindamycin levels in various body tissues and fluids. J Clin Pharmacol 1972;12:259-262.
46. Meares EM Jr: Prostatitis syndromes: New perspectives about old woes. J Urol 1980;123: 141-147.
47. Botto H, Camey M, Chretien P, et al: Study of the diffusion of roxitromycin into prostatic tissue after repeat oral dosing. Br J Clin Pract 1988;42(suppl 55):63.
48. Aleksandrov VP, Kniaz'kin IV, Zeziulin PN, Pecherskii AV: Wilprafen (josamycin) therapy of patients with urogenital inflammations (in Russian). Urologiia 2000;(6):23-24.
49. Giannopoulos A, Koratzanis G, Giamarellos-Bourboulis EJ, Panou C, Adamakis I, Giamarellou H: Pharmacokinetics of clarithromycin in the prostate: Implications for the treatment of chronic abacterial prostatitis. J Urol 2001;165: 97-99.
50. Maigaard S, Frimodt-Moller N, Hoyme U, Madsen PO: Rosoxacin and cinoxacin distribution in prostate, vagina and female urethra. An experimental study in dogs. Invest Urol 1979; 17:149-152.
51. Lambert T, Janpitre A, Voinnesson A, et al: Norfloxacin concentration in human prostatic tissues. 4th Mediterranean Congress of Chemotherapy, Rhodos, Greece, 1984.
52. Dan M, Golomb J, Gorea A, Lindner A, Berger SA: Penetration of norfloxacin into human prostatic tissue following single-dose oral administration. Chemotherapy 1987;33:240-242.
53. Naber KG, Soergel F, Kees F, et al: Norfloxacin concentration in prostatic adenoma tissue (patients) and in prostatic fluid in patients and volunteers. Proc 15th Int Congr Chemother, Landsberg, Germany. Landsberg, Ecomed, 1987, pp 1956-1958.
54. Schaeffer AJ, Darras FS: The efficacy of norfloxacin in the treatment of chronic bacterial prostatitis refractory to trimethoprim-sulfamethoxazole and/ or carbenicillin. J Urol 1990; 144:690-693.
55. Boerena JBJ, Dalhoff A, Debruyne FMY: Ciproflaxacin distribution in prostatic tissue and fluid following oral administration. Chemotherapy 1985;31:13-18.
56. Grabe M, Forsgren A, Bjork T: Concentrations of ciprofloxacin in serum and prostatic tissue in patients undergoing transurethral resection. Eur J Clin Microbiol 1986;5:211-212.
57. Dalhoff A, Weidner A: Diffusion of ciprofloxacin into prostatic tissue. Eur J Clin Microbiol Infect Dis 1988;7:438-439.
58. Naber KG, Soergel F, Kees F, Jaehde U, Schumacher H: Pharmacokinetics of ciprofloxacin in young (healthy volunteers) and elderly patients, and concentrations in prostatic fluid, seminal fluid, and prostatic adenoma tissue following intravenous administration. Am J Med 1989;87(suppl 5A):57S-59S.
59. Naber KG, Soergel F, Kinzig M, Weigel DM: Penetration of ciprofloxacin into prostatic fluid, ejaculate and seminal fluid in volunteers after an oral dose of 750 mg. J Urol 1993;150: 1718-1721.
60. Montay G, Tassel JP: Improved high-performance liquid chromatographic determinations of pefloxacin and its metabolite rorfloxacin in human plasma and urine. J Chromatogr 1985; 339:214-248.
61. Rannikko S, Malmborg A-S: Enoxacin concentration in human prostatic tissue after oral administration. J Antimicrob Chemother 1986;17:123.
62. Bergeron MG, Rejean R, Lessard C, Foucault P: Enoxacin penetration into human prostatic tissue. Antimicrob Agents Chemother 1988;32: 1433-1434.
63. Naber KG, Soergel F, Kees F, Schumacher H, Sigl G, Zurcher J, Berger S: Enoxacin-Konzentrationen in der Samenflüssigkeit, im Prostatasekret und im Prostataadenomgewebe nach oraler Gabe oder intravenöser Infusion. Infection 1989;17(suppl 1):S30-S36.
64. Ito Y, Fujimoto Y, Hasegawa Y, et al: Prostatic tissue levels of DL-8280. Chemotherapy (Tokyo) 1984;32(suppl 1):662-672.
65. Naber KG, Kinzig M, Sorgel F, Weigel D: Penetration of ofloxacin into prostatic tissue, ejaculate and seminal fluid. Infection 1993;21:96-100.
66. Leroy A, Grise P, Dhib M, Valtchev B, Fillastre JP: Penetration of lomefloxacin into human prostatic tissue. Urology 1991;38:192.
67. Naber KG, Sorgel F, Kees F, Schumacher H, Metz R, Grobecker H: In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue. J Antimicrob Chemother 1988;22(suppl D):199-207.
68. Kees F, Naber KG, Schumacher H, Grobecker H: Penetration of fleroxacin into prostatic secretion and prostatic adenoma tissue. Chemotherapy 1988;34:437-443.
69. Boerena JBJ, Bach D, Jol C, Pahlmann W: Penetration of rufloxacin into human prostatic tissue and fluid. J Antimicrob Chemother 1991; 28:547-554.
70. Suzuki K, Horida M, Ishikawa K, et al: Penetration of grepafloxacin in prostatic fluid and clinical study in urinary tract infections. Jpn J Chemother 1995;43(suppl 1):376-385.
71. Nielsen ML, Hansen I: Trimethoprim in human prostatic tissue and prostatic fluid. Scand J Urol Nephrol 1972;6:244-248.
72. Dabhoiwala NF, Bye A, Claridge M: A study of concentrations of trimethoprime-sulfamethoxazole in the human prostatic gland. Br J Urol 1976;4:77-81.
73. Oosterlinck W, Defoort R, Renders G: The concentration of sulfamethoxazole and trimethoprim in human prostate gland. Br J Urol 1975;47:301-304.
74. Winningham DG, Stamey TA: Diffusion of sulfonamides from plasma into prostatic fluid. J Urol 1970;104:559-563.
75. Robb CA, Carroll PT, Tippett LO, Langston JB: The diffusion of selected sulfonamides, trimethoprim and diaveridine into prostatic fluid. Invest Urol 1971;8:679-685.
76. Madsen PV, Kjaer TB, Baumueller A: Prostatic tissue and fluid concentrations of trimethoprim and sulfamethoxazole. J Urol 1976;8: 129-132.
77. Hofstetter A, Friesen A, Bishop-Freudling GB, Vergin H: Cotrimoxazole concentration in the prostatic fluid of patients with subacute and chronic prostatitis (in German). Fortschr Med 1984;102:244-246.
78. Dunn BL, Stamey TA: Antibacterial concentrations in prostatic fluid. 1. Nitrofurantoin. J Urol 1967;97:505-507.
79. Naber KG, Madsen PO: Antibiotics: Basic concepts; in Nickel JC (ed): Textbook of Prostatitis. Oxford, ISIS Medical Media, 1999, pp 83-94.